



**“AN AGTECH DEVELOPMENT COMPANY
ENABLING THE NEXT GENERATION OF
SAFER INSECTICIDES THAT ADDRESS
INSECTICIDE RESISTANCE”**

**Investor Briefing
November 2017**

BIO-GENE SNAPSHOT

An insecticide technology and IP development company

BETA-TRIKETONES
Platform Technology

Key technology enabling the next generation of safe insecticides to address the increasing problem of insecticide resistance

Data shows initial products **Flavocide™** & **Qcide™** can be highly effective for insect control management

Potentially suitable for commercialisation into multiple targeted insecticides

Collaborate with multinational AgChem partners to bring multiple insect indications to market

Targeting public health, animal health & crop protection verticals

EXECUTIVE SUMMARY

Novel insecticide platform leading to new potential products

- Unique (new) mode of action identified – alternative chemistry to current incumbent insecticides in a market seeking new products opening multiple market segments with multiple revenue sources

Strong test data

- Significant test results (and new tests underway with world leading institutions) demonstrate effectiveness of Flavocide™ at controlling resistant pests, as well as product safety

Initial multinational partnership secured

- Strategic testing partnership finalised with Virbac, a leading multinational animal health company with significant Virbac investment in product development supports Bio-Gene's partnership strategy

Manufacturing optimisation project underway with CSIRO

- To produce Flavocide™ at commercial rates and pricing

Established global patents

- Growing IP portfolio with additional applications filed

Appointment of new board members

- Diverse skill set with significant industry experience

BOARD & MANAGEMENT



DON BRUMLEY

Non-Exec. Chairman

- 25+ years as a senior partner and leader of Ernst & Young - Oceania
- Significant experience across IPOs, transactions, audit and advising growing entrepreneurial companies.
- Currently NED, Chairman of Audit and Risk Committee of Murray River Organics



RICHARD JAGGER

*Exec. Director &
CEO - Elect*


- 20+ years working in Agriculture Globally
- Most recently employed as Managing Director of Sinochem Australia
- Previously spent 15+ years at Monsanto in various management roles



ROBERT KLUPACS

Executive Director

- 30+ years corporate experience in international tech development
- Previously, MD and CEO of ASX-listed Circadian Technologies Ltd
- Previously, MD & CEO of ES Cell International Pte Ltd
- Registered Australian patent attorney



PETER MAY

Non-Exec. Director

- 20+ years experience in crop protection market with companies Orica & Crop Care Aus. (now Nufarm)
- Founded Xavca, providing consulting services to companies such as Syngenta & Sorex (BASF)
- Former CEO of BioProspect



KEVIN RUMBLE

Non-Exec. Director

- Founding Director of Bio-Gene
- 20+ years experience in new plant propagation, farming and live plant transport techniques
- Involved in the development of Qcide™ & development of Flavesone as a first step in the commercialisation of Flavocide™




ROGER MCPHERSON



*Chief Financial Officer &
Company Secretary*

- 15+ years experience as CFO and Company Secretary across both listed and unlisted companies
- Experience in the Pharma Manufacturing, Biotech, Biopharma industries
- Previously CFO and Co-Sec of TPI Enterprises (ASX:TPI)

GLOBAL PROBLEM: RESISTANCE & TOXICITY



THE CHALLENGE FOR AGCHEM



586 insect species now resistant to at least one insecticide class


Hundreds of thousands of molecules need to be screened now to find a new product

AgChem requires new chemistries but there is a challenge to finding new chemistries

Bio-Gene has a novel chemistry that it seeks to bring to market


Data: GT Brooks 1974, RL Metcalf 1980, W Klassen 1995, P McDougal 2003, CropLife 2011

NOVEL MODE OF ACTION (EXAMPLE CROP PROTECTION)



(Source: IRAC)

LARGE GLOBAL, GROWING MARKETS



Stable industry dominated by multi-national AgChem companies


Seeking, Safe New Solutions to complement off-patent insecticides

BIO-GENE
TECHNOLOGY
LTD

AgTech with access to new technology platform leading to new insecticides

BIO-GENE TECHNOLOGY APPROACH


Synthetic =
Replicable at
commercial quantities
(SCALABLE)



Near-term
consumer opportunities
available with QCide™

FLAVOCIDE™: A UNIQUE MODE OF ACTION

Comparison of the effects of Flavocide with other known insecticides on rat DRG membrane potential



Our collaborators have elucidated Flavesone MOA
IT DOES NOT act via mechanisms listed by IRAC

“Flavocide clearly exhibits a completely different profile compared to all other tested compounds in rat DRG neurones” – NeuroSolutions, August 2017

RESULTS TO DATE

Insect	Testing Entity	Market	Problem	FLAVESONE		COMMON INCUMBENT		FLAVESONE + CI COMBINATION	
				Speed	Efficacy	Speed	Efficacy	Speed	Efficacy
Aedes Mosquito	UTS	Public Health	Zika, Dengue Fever	✓	✓	✓	✓	✓✓	✓✓
Anopheles Mosquito (Resistant Strain)	Major Ag	Public Health	Malaria	✓	✓	✗	✗	In progress	In progress
Culex Mosquito	UTS	Public Health	Ross River Fever, West Nile	✓	✓	✓	✓	✓✓	✓✓
Domestic House Fly	UTS	Consumer	Salmonella, Gastroenteritis	✓	✓	✓	✗	✓✓	✓✓
Cattle tick (Resistant Strain)	Virbac	Animal Health	Transmits tick fever to range of animals	✓	✓	✗	✗	In progress	In progress
Buffalo Fly	Virbac	Animal Health	Attacks cattle resulting in weight loss etc	✓	✓	✓	✓	n/a	n/a
Flea	UTS	Animal Health	Skin infections, typhus & plague to people	✓	✓	✓	✓	n/a	n/a
Lesser Grain Borer (Resistant Strain)	QDAF	Grain Storage	Affect whole cereals (wheat, barley, rice & sorghum)	✓	✓	✗	✗	In progress	In progress


Speed and Efficacy shown across a range of insecticide resistant pests

For Information Only

LAB EFFICACY EXPERIMENTS (IN PROGRESS / AGREED)

	Insect	Testing Entity	Market	Problem
In Progress	Mites (Susceptible & Resistant)	Australian CRO	Crop Protection	Leaf desiccation, leaf drop, yield loss
	Beneficials	Australian CRO	General	Positive for crops etc. Control other pests, pollination etc.
	Aedes Mosquito (Resistant Strain)	Purdue	Public Health	Zika, Dengue Fever
	Buffalo Fly (Resistant Strain)	Virbac	Animal Health	Attacks cattle resulting in weight loss etc
	Ticks (Resistant Strains)	Purdue	Animal / Human	Transmission of various diseases (eg. Lyme)
Agreed	Other Grain Storage Pests (Resistant Strains)	QDAF	Grain Storage	Affect whole cereals (wheat, barley, rice & sorghum)
	Aphids (Susceptible & Resistant)	Australian CRO	Crop protection	Crop damage at high infestation levels
	Diamond Backed Moth	Australian CRO	Brassica crops	Damage to plant heads, contamination of produce
	Helicoverpa armigera	Australian CRO	Field Crops	Crop damage
	Brown Plant hopper	International CRO	Cereals	Feeding damage and viral transmission
	Silverleaf whitefly	International CRO	Horticulture	Feeding damage and disease transmission
	Culex Mosquito (Resistant Strain)	UTS	Public Health	Ross River Fever, West Nile
	Domestic House Fly (Resistant Strain)	UTS	Consumer	Salmonella, Gastroenteritis
	Cockroach (Susceptible & Resistant)	Purdue	Consumer	Pathogen transmission, allergic reactions
	Flea (Resistant Strain)	UTS	Animal Health	Skin infections, typhus & plague to people


GROWING INTELLECTUAL PROPERTY



Recent provisional patent filings which, when granted, extend patent life to **2038**

Further filings over next 6-24 months covering specific combinations, specific resistant pest control, new formulations, dose ranges etc

ADDING VALUE BY IMPROVING MANUFACTURING



CSIRO Collaboration	Results to Date...
<ul style="list-style-type: none">• Provides unique internal knowhow• Experts in process improvement• Collaboration commenced March 2017 – supported by CSIRO with \$50k “kick-start grant”	<ul style="list-style-type: none">• Yield improvement of >50%• Indicative cost reduction of >50%• Unique process developed• Further expected improvement over next 6-12 months

REVENUE GENERATION THROUGH MULTIPLE PARTNERING ARRANGEMENTS

Pre-Marketing

Generate data against key pests

Research fee

Collaborative Projects

Enter into stage gated partnership agreements on a segment by segment basis

Small up-front fee & purchase of active for further testing (\$50-250K) – Day 0

R&D Support for Bio-gene activities (tox, manufacture, etc) (\$500K-1M)

Licence Fees payable at development stage (\$500K-\$5M)

Royalty on Sales (3-6%)
48-60 months then ongoing

Ongoing Sales

Supply active material for partner formulation & sale

Each milestone has a news and value inflection point

VIRBAC – FIRST KEY AGREEMENT

Pre-Marketing

Data Generated ✓

Research on
cattle tick and
buffalo fly in
animal health

Collaborative Projects

Signed agreement with Virbac ✓

Small up-front fee & purchase
of active for further testing
(in progress)



R&D Support for Bio-gene
activities (tox, manufacture, etc)
(post-listing)

Licence Fees payable
at development stage

Royalty on Sales to
be agreed

Ongoing Sales

**Supply active material
into US\$400M+ market**

**Process duplicated for
each collaboration project**

UPCOMING MILESTONES

		H1 2018	H2 2018	H1 2019	H2 2019	H1 2020	H2 2020
Virbac	Progress Virbac Agreement to next stages						
	Initial mammalian toxicology studies						
	Product testing and toxicity data generation to support the AVPMA regulatory process						
	Sign Virbac License						
	First field trials						
	Registration Enabling Data						
	Registration Filed						
Additional activities	Results from research partner in activity in resistant mosquitoes, ticks and cockroaches						
	Initiation of expanded efficacy studies						
	Pursue near-term product opportunities with QCide™						
	Pursue further strategic partnerships						
	Secure supply chain & production						
	MoA Peer reviewed publication						
	File additional patents as appropriate						
	R&D to generate further data to support approaches to potential evaluation partners						

USE OF IPO PROCEEDS

A\$(000s)	Year 1	Year 2	Total
Source of Funds			
Cash at bank	1,850	3,841	1,850
Capital raising	7,100	-	7,100
R&D Tax Incentive	100	400	500
Interest Income	120	60	180
Subtotal	9,170	4,301	9,630
Uses of Funds			
Costs of the Offer	913	-	913
Flavocide™	2,450	1,930	4,380
Qcide™	240	190	430
Intellectual Property	100	100	200
Intellectual Property – Medibio	226	-	226
Management & Administration	1,400	1,450	2,850
Subtotal	5,329	3,670	8,999
Working capital at end	3,841	631	631

CAPITAL STRUCTURE

Capital Structure		
Category	Shares	% Total Shares
Existing shares	91,224,471	72.0%
\$7.1m capital raised in IPO at \$0.20 offer price	35,500,000	28.0%
Total	126,724,471	100%
Market capitalisation at listing	\$25.3 million	

- One loyalty option for every five shares held will be issued to eligible shareholders at a record date approximately three months post-listing on the ASX. These listed options will have an exercise price of \$0.20 and an expiry date approximately November 2018
- 17.3m shares subject to voluntary escrow (six months) & 22.3m shares subject to mandatory escrow (up to 24 months)

INVESTMENT OVERVIEW



New insecticide platform chemistry, beta-triketones demonstrating a novel mode of action



Enables products Flavocide™ & Qcide™ shown to be effective against insecticide resistant pests



Applications across multiple market segments including Public Health, Animal Health, Consumer Products and Crop Protection / Grain Storage



Significant opportunity for ongoing development through partnerships with major AgChem companies. First already signed with Virbac.



Collaborative approach per application can be duplicated across projects providing many product opportunities



Established global patents and intellectual property with additional applications filed



Appointment of new board members with diverse skill set with significant industry experience

CONTACT DETAILS

Bio-Gene Technology

Richard Jagger
CEO elect
+61 3 9628 4178
bgt.info@bio-gene.com.au

Roger McPherson
Company Secretary
+61 3 9628 4178
bgt.info@bio-gene.com.au

Media/investor relations
Matthew Wright
+61 451 896 420
matt@nwrcommunications.com.au

DISCLAIMER

- This presentation (“this Presentation”) has been prepared by Bio-Gene Technology Limited [ABN 32 071 735 950] (“BGT” or the “Company”) and is dated 28 November 2017.
- This Presentation contains summary information about the current activities of BGT as at the date of this Presentation. The information in this Presentation is of a general nature and does not purport to be complete. This Presentation does not purport to contain all the information that an investor should consider when making an investment decision nor does it contain all the information which would be required in a disclosure document or prospectus prepared in accordance with the requirements of the Corporations Act. It should be read in conjunction with the Company’s other periodic and continuous disclosure announcements lodged with the ASX, which are available at the ASX website www.asx.com.au under the code “BGT”. Neither BGT nor its directors, employees or advisers give any warranties in relation to the statements and information in this Presentation. Neither BGT nor its directors, employees or advisers accept any responsibility to inform recipients specifically of any matter arising or coming to its attention after the date of this Presentation. Recipients should monitor BGT’s announcements to ASX, which can be obtained from ASX website as referred to above.
- An investment in BGT’s Shares is subject to investment risks and other known and unknown risks, some of which are beyond the control of the Company. BGT does not guarantee any particular rate of return or the performance of BGT, nor does it guarantee the repayment of capital from BGT or any particular tax treatment.
- This Presentation is for information purposes only. It is not a prospectus, disclosure document, product disclosure statement or other offering document under Australian law or any other law (and will not be lodged with ASIC and is not approved by or registered with any regulator). The Presentation is not and should not be considered an offer or an invitation to acquire shares or any other securities or financial products.
- This Presentation may not be released or distributed in the United States. This Presentation does not constitute an offer to sell, or a solicitation of an offer to buy, securities in the United States or in any other jurisdiction in which such an offer would be illegal. The New Shares have not been, and will not be, registered under the U.S. Securities Act of 1933, as amended (the “U.S. Securities Act”) or the securities laws of any state or other jurisdiction of the United States. Accordingly, the New Shares may not be offered or sold, directly or indirectly, in the United States.
- The distribution of this Presentation in other jurisdictions outside Australia may also be restricted by law and any such restrictions should be observed. Any failure to comply with such restrictions may constitute a violation of applicable securities laws.
- This Presentation does not constitute financial product or investment advice (nor tax, accounting or legal advice) nor is it a recommendation to acquire shares and does not and will not form any part of any contract for the acquisition of shares. This Presentation has been prepared without taking into account the objectives, financial situation or needs of any particular investor.
- Before making an investment decision, prospective investors should consider the appropriateness of the information having regard to their own objectives, financial situation and needs and seek appropriate advice, including financial, legal and taxation advice appropriate to their jurisdiction. BGT is not licensed to provide financial product advice in respect of BGT shares or any other investment.
- Any trademarks in this Presentation are used for the purposes of identification only and does not indicate endorsement of BGT or this Presentation by the trademark’s owner(s) or users. Each trademark is the property of its respective owner(s).
- This Presentation may contain forward looking statements, opinions or estimates. Any forward looking statements, opinions or estimates contained in this Presentation are not guarantees or predictions of future performance and involve known and unknown risks and uncertainties and other factors, many of which are beyond the control of BGT, and may involve significant elements of subjective judgement and assumptions and contingencies as to future events which may or may not be correct which are subject to change without notice, as are statement about market and industry trends, which are based on interpretations of current market conditions. Those statements reflect views only as at the date of this Presentation. The actual results may differ materially from anticipated results, performance of achievement expressed, projected or implied by these forward looking statements. While BGT believes the statements in the Presentation are reasonable, neither BGT nor any other person gives any assurance or guarantee that the occurrence of the events expressed or implied in the Presentation will actually occur and investors are cautioned not to place undue reliance on those statements. There can be no assurance that actual outcomes will not differ materially from these forward-looking statements. A number of important factors could cause actual results or performance to differ materially from the forward looking statements, including the risk factors set out in this Presentation. Investors should consider the forward looking statements contained in this Presentation in light of those disclosures. The forward looking statements are based on information available to BGT as at the date of this Presentation. Except as required by law or regulation (including the ASX Listing Rules), BGT accepts no obligation to provide any additional or updated information whether as a result of new information, future events or results or otherwise. Indications of, and guidance or outlook on, future earnings or financial position or performance are also forward looking statements.
- To the maximum extent permitted by law, no representation or warranty and take no responsibility for, express or implied, is made as to the currency, accuracy, reliability or completeness of information statements, opinions, conclusions or representations contained in this Presentation and BGT and its respective advisers, affiliates, related bodies corporate, directors, officers, partners, employees and agents excludes and disclaims all liability (however caused), including without limitation for negligence or for any expenses, losses, damages or costs incurred by you.
- BGT makes no recommendations as to whether any person should acquire securities of the Company. Opinions expressed herein are current opinions only as of the date indicated and are subject to change. This presentation does not constitute, and shall not be relied upon, as a promise, representation, warranty or guarantee as to the past, present, or future performance of BGT or any other matter.